Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy

References

• Moalli PA, Talarico LC, Sung VW, et al. Impact of menopause on collagen subtypes in the arcus tendineous fasciae pelvis. Am J Obstet Gynecol 2004;190:620–7
   PubMed Web of Science ®Google Scholar
• Tinelli A, Malvasi A, Rahimi S, et al. Age-related pelvic floor modifications and prolapse risk factors in postmenopausal women. Menopause 2010;17:204–12
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13: 509–22
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000;61:3090–6
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Julia MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005;52(Suppl 1):S46–52
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) – results from an international survey. Climacteric 2012;15:36–44
   PubMed Web of Science ®Google Scholar
• The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19:257–71
   PubMed Web of Science ®Google Scholar
• The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14:357–69
   Web of Science ®Google Scholar
• Birkhauser MH, Reinecke I. Current trends in hormone replacement therapy: perceptions and usage. Climacteric 2008; 11:192–200
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: Non-contraceptive estrogen drug products for the treatment of vasomotor symptoms and vulvar and vaginal atrophy symptoms – Recommended prescribing information for health care providers and patient labeling 2005
   Google Scholar
• Vagifem estradiol vaginal tablets prescribing information. Princeton, NJ: Novo Nordisk Inc; Nov 25, 2009
   Google Scholar
• Wang S, Paris F, Sultan CS, et al. Recombinant cell ultrasensitive bioassay for measurement of estrogens in postmenopausal women. J Clin Endocrinol Metab 2005;90:1407–13
   PubMed Web of Science ®Google Scholar
• Santen RJ, Demers L, Ohorodnik S, et al. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 2007;72:666–71
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Lee JS, Santen RJ. Standardization of steroid hormone assays: why, how, and when?Cancer Epidemiol Biomarkers Prev 2007;16:1713–19
   PubMed Web of Science ®Google Scholar
• Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 μg 17β-estradiol vaginal tablets. Climacteric 2010;13:219–27
   PubMed Web of Science ®Google Scholar
• Maamari RV. Treatment of vaginal atrophy with ultra-low-dose 10 mcg estradiol vaginal tablets. US Obstetrics & Gynecology 2011;6:47–50
   Google Scholar
• Ulrich LS, Naessen T, Elia D, Goldstein JA, Eugster-Hausmann M. Endometrial safety of ultra-low-dose Vagifem 10 μg in postmenopausal women with vaginal atrophy. Climacteric 2010;13: 228–37
   PubMed Web of Science ®Google Scholar
• Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1053–60
   PubMed Web of Science ®Google Scholar
• Panay N, Maamari R. Treatment of postmenopausal vaginal atrophy with 10-mg estradiol vaginal tablets. Menopause Int 2012;18:15–19
   PubMedGoogle Scholar
• Furness S, Roberts H, Marjoribanks J, Lethaby A, Hickey M, Farquhar C. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2009:CD000402
   Google Scholar
• Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol 2010;116:876–83
   PubMed Web of Science ®Google Scholar
• Green PK, Weiss NS, McKnight B, Voigt LF, Beresford SA. Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States). Cancer Causes Control 1996;7:575–80
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: Estrogen and estrogen/progestin drug products to treatment of vasomotor symptoms and vulvar and vaginal atrophy symptoms – Recommendations for clinical evaluation 2003
   Google Scholar
• Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006:CD001500
   PubMed Web of Science ®Google Scholar
• Palacios S. Managing urogenital atrophy. Maturitas 2009;63: 315–18
   PubMed Web of Science ®Google Scholar
• Simon JA. Vulvovaginal atrophy: new and upcoming approaches. Menopause 2009;16:5–7
   PubMed Web of Science ®Google Scholar
• Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6:2133–42
   PubMed Web of Science ®Google Scholar
• Simon J, Kingsberg S, Maamari R, Goldstein J, Nappi RE. The Partners’ Survey: Impact of vaginal discomfort and its treatment – insights, views, and attitutes of postmenopausal women and their partners [abstract S-17 from 23rd Annual Meeting of NAMS]. Menopause 2012;19:1376
   Google Scholar
• Krychman M. Impact of vaginal atrophy on quality of life and sexuality. OBG Management 2010;November Suppl:S14–19
   Google Scholar
• Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242–55
   PubMed Web of Science ®Google Scholar
• Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010;17:194–203
   PubMed Web of Science ®Google Scholar
• Nappi RE, Lachowsky M. Menopause and sexuality: prevalence of symptoms and impact on quality of life. Maturitas 2009;63: 138–41
   PubMed Web of Science ®Google Scholar
• Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency – a pharmacokinetic and pharmacodynamic study. Maturitas 1992;15:121–7
   PubMed Web of Science ®Google Scholar
• Foidart JM, Vervliet J, Buytaert P. Efficacy of sustained-release vaginal oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas 1991;13:99–107
   PubMed Web of Science ®Google Scholar
• Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7:156–61
   PubMed Web of Science ®Google Scholar
• Nachtigall LE. Clinical trial of the estradiol vaginal ring in the U.S. Maturitas 1995;22(Suppl):S43–7
   PubMedGoogle Scholar
• Mettler L, Olsen PG. Long-term treatment of atrophic vaginitis with low-dose oestradiol vaginal tablets. Maturitas 1991;14: 23–31
   PubMed Web of Science ®Google Scholar
• Bachmann G, Bouchard C, Hoppe D, et al. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause 2009;16:719–27
   PubMed Web of Science ®Google Scholar